Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06997549 · ClinicalTrials.gov registry record
Retrospective Analyses of the Greenbrook Database Evaluating Mental Health Treatments
A clinical trial of Depression and OCD, sponsored by Neuronetics.
- Recruiting
- Registry status
- 12,000
- Enrollment target
- 1
- Study location
NCT06997549 is a study of Depression and OCD that is actively recruiting participants, run by Neuronetics. The registered enrollment target is 12,000 participants, above the 769-participant average among 679 other Depression trials with a reported enrollment target (1460% higher). The trial reports 1 study location across 1 state.
The verdict
NCT06997549, a study of Depression and OCD, is actively recruiting participants, sponsored by Neuronetics.
- RECRUITING
- Registry status
- 12,000 participants
- Enrollment target
- 1
- Study location
Study Summary
The study involves multiple retrospective analyses to understand the utilization of mental health treatments provided at Greenbrook and their effectiveness
Conditions Studied
Interventions
- DEVICE Patients treated with NeuroStar TMS
- DRUG Patients treated with Esketamine
Study Locations (1)
Pennsylvania
- Neuronetics - Malvern
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12,000 participants |
| Start Date | 2025-05-15 |
| Est. Completion | 2035-12 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06997549
The ClinicalTrials.gov registry entry for NCT06997549 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 12,000 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 769-participant average among 679 other Depression trials with a reported enrollment target (1460% higher). The listed sponsor is Neuronetics, which has 11 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Depression appearing as the primary indexed condition, and to 2 interventions - of which Patients treated with NeuroStar TMS is the first listed.
NCT06997549 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT06997549 about?
NCT06997549 is a clinical study titled "Retrospective Analyses of the Greenbrook Database Evaluating Mental Health Treatments". The study involves multiple retrospective analyses to understand the utilization of mental health treatments provided at Greenbrook and their effectiveness
What is the current status of trial NCT06997549?
This trial is currently recruiting. The enrollment target is 12,000 participants. The study started on 2025-05-15. Estimated completion is 2035-12.
What conditions does trial NCT06997549 study?
This clinical trial studies the following conditions: Depression, OCD, Anxiety Depression.
What interventions are being tested in trial NCT06997549?
The interventions under investigation include: Patients treated with NeuroStar TMS (DEVICE), Patients treated with Esketamine (DRUG).
Who is sponsoring clinical trial NCT06997549?
This trial is sponsored by Neuronetics, which has 11 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06997549 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Depression
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Reaching Out to Distressed Medical Residents, Fellows and Faculty
RECRUITING · NA
-
Depression and Driving
RECRUITING
-
Neuropharmacologic Imaging and Biomarker Assessments of Response to Acute and Repeated-Dosed Ketamine Infusions in Major Depressive Disorder
RECRUITING · Phase 1
-
Sleep to Reduce Incident Depression Effectively in Peripartum
RECRUITING · Phase 2
-
PET Imaging of Cyclooxygenase in Participants With Major Depressive Disorder (MDD)
RECRUITING · Phase 1
-
Identifying and Treating Depression in the Orthopaedic Trauma Population
RECRUITING · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.